WEE1 kinase has been described as a major gate keeper at the G2 cell cycle checkpoint and to be involved in tumour progression in different malignant tumours. Here we analysed the expression levels of WEE1 in a series of melanoma patient samples and melanoma cell lines using immunoblotting, quantitative real-time PCR and immunohistochemistry. WEE1 expression was significantly downregulated in patient samples of metastatic origin as compared with primary melanomas and in melanoma cell lines of high aggressiveness as compared with cell lines of low aggressiveness. Moreover, there was an inverse correlation between the expression of WEE1 and WEE1-targeting microRNA miR-195. Further analyses showed that transfection of melanoma cell lines with miR-195 indeed reduced WEE1 mRNA and protein expression in these cells. Reporter gene analysis confirmed direct targeting of the WEE1 3 0 untranslated region (3 0 UTR) by miR-195. Overexpression of miR-195 in SK-Mel-28 melanoma cells was accompanied by WEE1 reduction and significantly reduced stress-induced G2-M cell cycle arrest, which could be restored by stable overexpression of WEE1. Moreover, miR-195 overexpression and WEE1 knockdown, respectively, increased melanoma cell proliferation. miR-195 overexpression also enhanced migration and invasiveness of melanoma cells. Taken together, the present study shows that WEE1 expression in malignant melanoma is directly regulated by miR-195. miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells.
INTRODUCTION
WEE1 kinase has been reported as a G2 checkpoint regulator by directly phosphorylating and inhibiting Cdc2, the major cyclindependent kinase inducing G2-M progression in cell cycle. 1 Initially, WEE1 was identified in Schizosaccharomyces pombe through genetic studies of cell size control and cell cycle progression. Further work established WEE1 as a tyrosine kinase, which belongs to Ser/Thr family of protein kinases.
1 WEE1 induces an inhibitory tyrosine (Y15) phosphorylation of Cdc2/cyclin B kinase to prevent G2-M transition during cell cycle. 2 Recently, WEE1 kinase has been described as a major gate keeper at the G2 cell cycle checkpoint in glioblastoma and might be a potential treatment target for this tumour. 3 Microarray data from melanoma revealed that WEE1 is slightly upregulated in primary melanomas as compared with benign nevi and normal skin tissues. 3, 4 Inhibition of WEE1 has been reported to be a potential new strategy for cancer therapy based on experiments in some p53-null tumours, such as glioblastoma, cervical, colon and ovarian carcinoma. [3] [4] [5] [6] However, downmodulation of WEE1 has also been reported to be associated with tumourigenesis and significantly higher recurrence rate in non-small-cell lung cancer. 7 Overall, the role of WEE1 in p53-positive tumours such as malignant melanoma and specifically in metastatic lesions is not well established and requires further elucidation.
MicroRNAs (miRNA) are 21-23 nucleotide (nt) noncoding RNA molecules that regulate gene expression by targeting the 3 0 untranslated region (3 0 UTR) of mRNAs with consecutive inhibition of protein translation or degradation of target mRNA. 8 Several studies indicate that miRNAs may be either underexpressed in tumours with consecutive upregulation of oncogenes, or overexpressed with consecutive downregulation of tumour suppressor genes and thereby contribute to tumour progression. [9] [10] [11] [12] [13] [14] Malignant melanoma, a cancer of the pigment-producing cells of the skin is highly metastatic and relatively resistant to standard chemotherapy in the metastatic stage. 15 The high tumourigenic potential of melanoma cells was shown in a recent study, where up to 65% of single melanoma cells formed tumours when injected into NOD/SCID IL2Rg null mice. 16 In order to identify miRNAs with a putative role in melanoma progression, several miRNA expression studies have been performed, which identified a number of dysregulated miRNAs. In one study, miR-221 and miR-222 expression was found to increase with melanoma progression. 17 Overexpression of these miRNAs in Me1402/R melanoma cell line enhanced the tumourigenic potential of these cells by downregulating c-KIT receptor and p27Kip1. 17 In another study, miRNA let-7a was shown to be strongly expressed by melanocytes and downregulated or lost in melanoma cell lines. 18 Several miRNAs exhibit distinct expression signatures in metastatic melanomas compared with primary tumours. In one such study involving 10 cell lines and 20 patient samples representing nevi and primary or metastatic melanoma, miRNA-200c was consistently downregulated in melanocytes, melanoma cell lines and patient samples. miR-195 has been of particular interest in recent years due to its involvement in cell cycle regulation and pro-proliferative activity. 20 Interestingly, normal cell growth of human embryonic stem cells after perturbation of miRNA pathway can be restored by introduction of miRNAs miR-195 and miR-372, respectively, attributing to miR-195 a central role in cellular proliferation. 20 It is a top candidate for WEE1 targeting according to current target prediction algorithms with two highly conserved binding sites (www.targetscan.org). In one study, miR-195 was found to be downregulated in colorectal cancer and its ectopic expression in colorectal cancer cell lines HT29 and LoVo suppressed tumourigenicity by directly targeting Bcl-2. 21 In contrast, miR-195 was found to be overexpressed in temozolomide-resistant U251MG glioblastoma multiforme cells. 22 Inhibition of miR-195 in combination with temozolomide strongly enhanced the cytotoxic effect by an as yet unidentified mechanism. 22 Thus, the role of miR-195 may be either tumourigenic or inhibitory in tumour cells depending on the cellular background and experimental conditions.
In this study, we analysed expression levels of WEE1 and miR-195 in primary melanomas and melanoma metastases and identified an inverse correlation between WEE1 and miR-195 expression levels in distant cutaneous metastases and primary melanomas with distant metastases showing downregulated WEE1 and upregulated miR-195. The biological relevance of these findings was analysed in melanoma cells lines in vitro.
RESULTS

WEE1 is downregulated in melanoma metastases as compared with primary melanomas
A detailed investigation on the role of WEE1 in melanoma metastasis has not yet been performed. To address this issue, we first performed immunohistochemical staining of primary melanoma and melanoma metastasis tissues for WEE1. As shown in Figures 1a and b the percentage of cells positively staining for WEE1 was significantly lower in melanoma metastases compared with primary melanomas (13.1 ± 3.0% versus 56.3 ± 3.1%). WEE1 expression was further analysed on the mRNA level in eight lasermicrodissected primary melanomas and eight distant cutaneous metastases by quantitative real-time PCR (qRT-PCR). The expression of WEE1 mRNA was significantly lower (42-fold) in distant cutaneous metastases as compared with primary melanomas (Figure 1c) .
To further validate WEE1 downregulation in metastatic melanoma cells on the protein level, expression of WEE1 was analysed in non-metastatic (BRO, A-375, 1F6, and RPM-MC) and metastatic melanoma (SK-Mel-147, SK-Mel-28, SK-Mel-29) cell lines using immunoblotting. Interestingly, WEE1 expression was found to be significantly reduced (41.6-fold) in metastatic cell lines as compared with non-metastatic cell lines (Figure 1d , Supplementary Figure 1 ). Thus, there appears to be an inverse correlation between WEE1 protein expression and aggressiveness of melanoma cells. Taken together, our data show that WEE1 is downregulated during melanoma progression and metastatic lesions might rely on WEE1 downregulation. miR-195 is upregulated in melanoma metastases as compared with primary melanomas In different miRNA target databases (www.targetscan.org, www.pictar.mdc-berlin.de, www.microrna.org, www.diana.cslab. ece.ntua.gr/microT), WEE1 was predicted to be a conserved target for mainly three miRNAs, namely miR-195 (miR-15/16/195/424/497 cluster), miR-155 and miR-372 (miR-106/302 cluster). Two conserved miRNA binding sites for miR-195 and one site for miR-155 and miR-372, respectively, were identified in the WEE1 3 0 UTR region (www.targetscan.org). As miR-155 was reported to be downregulated in malignant melanoma, 23 we selected miR-195 and miR-372 for further analysis. Using TaqMan miRNA assays these miRNAs were screened in the same cohort of lasermicrodissected primary melanomas and distant cutaneous metastasis samples, which were used for screening of WEE1 mRNA expression. The miRNA expression levels were normalized to RNU48 levels. miR-195 was found to be significantly upregulated in cutaneous metastases as compared with primary melanoma samples while miR-372 was downregulated (Figures 2a  and b (Figures 3f and g ). Taken together, these findings provided strong evidence that miR-195 inhibits WEE1 expression by directly targeting its 3 0 UTR in melanoma cells. Furthermore, the percentage of cells in the G0-G1 upon WEE1 knockdown was significantly increased, which indicates that WEE1 depletion might be beneficial for the melanoma cells to escape the G2-M arrest and at least partly re-enter cell cycle (Figures 4d and e) . Doxorubicin only slightly induced endogenous miR-195 (Supplementary Figure 3) , suggesting that induced endogenous miR-195 did not significantly contribute to G2-M abrogation in these experiments. Taken together, these data provide strong evidence that under conditions of DNA damage mediated by the chemotherapeutic agents, miR-195 is able to significantly downregulate the G2-M cell cycle arrest via downmodulating WEE1 in melanoma cells. To further substantiate the role of miR-195 in melanoma progression, we analysed its effects on melanoma cell proliferation, migration and invasiveness under normal conditions. Interestingly, transfection of miR-195 and WEE1-specific siRNA, respectively, in melanoma cells significantly enhanced cell proliferation after 48 and 72 h ( Figure 6 ). Depletion of endogenous miR-195 using a miR-195-specific antagomiR slightly reduced proliferation, but this effect did not reach significance levels ( Figure 6 ). miR-195-transfected cells were more efficient than control cells in closing an artificial wound created over a confluent monolayer both in presence or absence of a 3D matrigel overlay (Figures 7a  and b, Supplementary Figure 4) . WEE1 knockdown did not alter the migratory capacity of melanoma cells, suggesting that miR-195 enhances melanoma cell migration in a WEE1-independent manner (Figure 7a) . Furthermore, the migratory capacity of melanoma cells was reduced by a miR-195-specific antagomiR (Figure 7a, Supplementary Figure 4) . Taken together, miR-195 has a significant impact on proliferation and migratory capacity of melanoma cells. DISCUSSION WEE1 kinase has been described as a major gate keeper at the G2-M cell cycle checkpoint. 2, 3 Evidence has been provided that in particular tumour cells lacking intact p53/p21 pathway largely rely on checkpoint kinase 1 (Chk1)/WEE1/Cdc2 pathway for G2 checkpoint control under genotoxic stress. 3, 6 However, the role of Chk1/WEE1/Cdc2 pathway for G2 checkpoint control in malignant melanoma is poorly understood. In a recent study, high expression of WEE1 and other DNA repair genes such as RAD51, RAD52, RAD54, BRCA1 and CHEK1 in primary melanomas were associated with poor prognosis in melanoma patients. 24 WEE1 was not among the top 10 candidate genes but had a significant negative correlation with the recurrence-free survival of melanoma patients. This study provided first evidence that WEE1 might have a role in melanoma biology. Here, we analysed expression levels of WEE1 in a series of patient samples from primary melanomas, melanoma metastases and different melanoma cell lines using immunohistochemistry, immunoblotting and qRT-PCR. Surprisingly, WEE1 expression was significantly downregulated in patient samples of metastatic origin as compared with primary melanomas and in melanoma cell lines of high aggressiveness as compared with cell lines of low aggressiveness. Thus, in contrast to a possible tumour-promoting role of WEE1 in primary melanomas, metastatic lesions might rely on WEE1 downregulation instead of WEE1 upregulation. Interestingly, in a study of Mir et al. 3 on glioblastoma, WEE1 expression was also tested in melanoma samples and found to be low compared with WEE1 levels in other tumour entities.
As mentioned above, WEE1 is a major checkpoint kinase for G2-M arrest. Inactivation or low expression levels of checkpoint molecules such as p53 is often due to inactivating mutations or epigenetic mechanisms. In recent studies, miRNAs have been described as major regulators of tumour development and progression and regulators of checkpoint molecules such as p53, p21, p27, p57. 25 Therefore, we addressed the question whether miRNAs might be involved in WEE1 downregulation in melanoma metastases.
Different miRNA target databases mention WEE1 as a wellconserved miR-195 target. miRNA-195 is encoded by a highly conserved miRNA cluster located on chromosome 17(17p13.1), which includes miR-15/16/195/424/497 (www.mirbase.org). Although some studies show that miR-195 is downregulated in different tumours, 26, 27 suggestive for a role as tumour suppressor, in the present study miR-195 was found to be overexpressed in melanoma metastases and metastatic cell lines as compared with primary melanomas and non-metastatic melanoma cell lines, respectively. Notably, the role of miR-195 in promoting tumourigenesis and specially metastasis has not been investigated so far. Recent evidences demonstrate that miRNAs may be tumourigenic and tumour-suppressive depending on the developmental lineage of the cells, the stage and cell-specific environment. 28 For example, initially the miR-17B92 cluster showed increased expression in both small-cell lung cancers and human B-cell lymphomas and was shown to have a key role in tumourigenesis. 29, 30 However, some recent studies implicated this cluster to be a potent tumour suppressor and found it to be deleted in several tumour types including malignant melanoma. 31, 32 Thus, tissue-specific factors and factors of the microenvironment may influence the role of miRNAs in individual tumours.
In recent years, evidence has been provided for miRNAmediated cell cycle regulation in melanoma cells. 17, 31 Although WEE1 has been shown to be regulated at different levels either positively by Chk1 or negatively by polo-like kinase 1, p53 and transcription factor such as Klf2, [33] [34] [35] miRNA-mediated regulation of WEE1 has not been thoroughly investigated. In an earlier study on human embryonic stem cells, it was shown that miR-195 overexpression was sufficient to enhance cell proliferation in H1 hESCs. 20 Thus, there seems to be a positive relation between miR-195 overexpression and unlimited growth at least in stem cells. Expression analysis in this study revealed an inverse correlation between the expression of WEE1 and miR-195 in melanoma samples, supportive for an interaction between both. Reporter gene assays demonstrated that WEE1 is indeed a specific and direct target of miR-195. Interestingly, the WEE1 gene carries two binding motifs for miR-195 in its 3 0 UTR, both of which appear to contribute to WEE1 downregulation, as shown by reporter gene analyses with normal and mutated constructs. It is well understood that higher numbers of binding motifs for miRNAs in 3 0 UTRs of genes indicate higher biological relevance of this interaction, 8 further supporting the biological relevance of our findings.
We found that under normal conditions, miR-195 overexpression significantly increased proliferation as well as migratory and invasive potential of melanoma cells. Thus, miR-195 may in vivo contribute to melanoma progression by these mechanisms. To address the possible role of miR-195 in WEE1-mediated G2 checkpoint control, melanoma cells were exposed to doxorubicin, cisplatin or vinblastine, common genotoxic stress-inducing chemotherapeutic agents. Transient overexpression of miR-195 in these experiments significantly reduced G2-M arrest, which indicates that miR-195 might have an important role for G2 checkpoint control under stress conditions. Abrogation of G2-M arrest was associated with WEE1 downregulation. These findings are in line with a previous study where abrogation of stressinduced G2-M arrest was observed upon WEE1 inhibition with the small molecule inhibitor MK-1775 in p53-deficient colon carcinoma cells.
36 G2-M checkpoint abrogation was found to enhance the efficacy of DNA-damaging agents such as 5-fluorouracil, pemetrexed, doxorubicin, camptothecin and mitomycin C, leading to increased apoptosis in WiDr human colon cancer cells. 37 In the present study, the percentage of cells in the G0-G1 significantly increased upon miR-195-mediated WEE1 knockdown in doxorubicintreated cells.
Depletion of WEE1 in U2OS osteosarcoma cell line was shown to induce DNA damage in actively replicating cells. 38 Thus, WEE1 downregulation during melanoma progression might theoretically render metastatic melanoma more sensitive to chemotherapeutic agents. This is indeed not the case as melanoma is a largely treatment-resistant tumour to chemotherapy. 15 This obvious contradiction may be explained by the fact that the miRNA levels used in our study for WEE1 downregulation under genotoxic stress far exceeded normal levels in melanoma cells (by more than 100-fold). Normal, untransfected melanoma cells were indeed able to mount a significant G2-M arrest after genotoxic stress. On the basis of these findings, we propose a model in which miRNA-195 finetunes WEE1 expression in vivo in metastatic lesions to support premature re-entry into cell cycle and thereby facilitate uncontrolled growth in metastatic lesions.
This premature entry into cell cycle (and increased proliferation) finally leads to accumulation of mutations as a hallmark of many cancers and renders cells even more aggressive. 39 In line with this, loss of WEE1 was suggested to have a tumour-promoting role in non-small-cell lung cancer. 7 In this study, patients with WEE1-negative tumours showed significantly higher recurrence rates than those with WEE1-positive tumours. 7 Taken together, the present study shows that WEE1 is directly regulated by miR-195 in malignant melanoma. The inverse correlation between both in metastatic lesions with increased levels of miR-195 and low WEE1 levels may support the clinical relevance of these findings. Indeed, in vitro experiments showed that miR-195 may help to overrun G2 arrest in melanoma cells and thereby support metastatic growth.
MATERIALS AND METHODS
Melanoma tissues and cell lines
For immunohistochemical analyses, 10 samples of paraffin-embedded material from primary malignant melanomas and distant cutaneous melanoma metastases, respectively, was used. For detection of miRNA expression, cryopreserved material from eight primary malignant melanomas and eight distant cutaneous melanoma metastases, respectively, was used. Analyses of patient material were done after informed consent of patients and approved by the local Ethics Committee ( 
Immunohistochemical staining
Immunohistochemical staining was performed on formalin-fixed paraffinembedded tissue using anti-WEE1 mouse monoclonal Ab (sc-5285). VECTASTAIN Elite ABC kit and ImPACT DAB Peroxidase Substrate (both from Vector Laboratories Inc, Burlingame, CA, USA) were used for immunohistochemical staining. Counterstaining was performed with hematoxylin. Immunoreactivity was scored by calculating the percentage of positively staining cells of minimal 400 cells evaluated in different highpower fields ( Â 40). miRNA extraction and quantification by real-time PCR Samples were individually screened for the expression of miR-195 and miR-372, using commercially available TaqMan MicroRNA Assays (#000494, #000560; Applied Biosystems, Darmstadt, Germany). WEE1 expression was determined with TaqMan Gene Expression Assays (#Hs00268721_m1) according to the manufacturer's specifications. PCR amplification and signal detection of amplified miRNAs and genes were performed using a StepOne Real-Time PCR System (Applied Biosystems). C t (threshold cycle) values of real-time PCR for miRNAs were normalized to those of RNU48 (U48 small nucleolar RNA; #001006). GAPDH was used as normalization control.
siRNA transfection and treatment with genotoxic agents SK-Mel-28 cells were seeded in either 24-well or 6-well plates. In total, 40 nM siRNA (WEE1 siRNA #L-005050-00-0005, non-targeting siRNA #D-001810-10-05) or 100 nM each of mature miRNA mimics (miR-195 #C-300643-03-0005), antagomiR (#195-IH-300643-05-0005), mimic negative control (#1-CN-001000-01-05) from Dharmacon RNAi Technologies, Thermo Fisher Scientific, (Lafayette, CO, USA), using lipofectamine RNAimax reagent (Invitrogen, Karlsruhe, Germany). Genotoxic stress was induced by addition of 100 nM doxorubicin-HCl for 2 h, or 40 nM of vincaleukoblastine sulphate (vinblastine) for 10 min, or 6 mM of cisplatinum(II) diammine dichloride (cisplatin), all purchased from SigmaAldrich (Munich, Germany) for 48 h. At 24 h after doxorubicin or vinblastine and 48 h after cisplatin treatment, cells were harvested for immunoblotting and cell cycle analysis.
Immunoblotting
Immunoblotting was performed as described. 40 The following primary antibodies were used (all purchased from Santa Cruz Biotechnologies, Santa Cruz, CA, USA): anti-WEE1 mouse monoclonal Ab (sc-5285), antipCdk1 rabbit polyclonal Ab (sc-7989). Anti-b-actin mouse monoclonal Ab (sc-5274) was used to verify equal loading of proteins. The following secondary antibodies were used for immunodetection (all from LI-COR Biosciences, Bad Homburg, Germany): IRDye 680LT goat anti-rabbitIgG (926-68021) and IRDye 800CW donkey anti-mouseIgG (926-32212). Immunodetection and quantification of protein bands was performed with a LI-COR Odyssey scanner using Odyssey 3.0 software (LI-COR Biosciences).
Cell cycle analysis
Ethanol-fixed cells were centrifuged at 3000 r.p.m. for 5 min, washed twice with phosphate-buffered saline and then incubated with 0.5 ml phosphatebuffered saline containing 0.1 mg/ml RNase A and 50 mg/ml propidium iodide for 30 min at room temperature. The cell cycle distribution was analysed using BD-FACSCalibur (BD Biosciences Pharmingen, San Diego, CA, USA).
Luciferase reporter assay
Luciferase reporter gene assay was performed as described. 20 The wildtype WEE1 3 0 UTR, single-or double-mutated WEE1 3 0 UTR constructs or empty pSGG-plasmid were cotransfected with miR-195 mimics into SK-Mel-28 or SK-Mel-147 cells. SK-Mel-147 cells were also individually transfected with either empty pSGG-plasmid or WEE1 3 0 UTR construct alone or in combination with miR-195 mimics. After 48 h, luciferase activity of pSGG constructs was measured using the Dual-Luciferase Reporter Assay System (Promega GmbH, Mannheim, Germany).
Proliferation assay
At 24 h after transfection of SK-Mel-147 cells with non-targeting control, miR-195, WEE1 specific siRNA or antagomiR against miR-195, cells were seeded on a 96-well plate (4 Â 10 3 cells/well). Proliferation was analysed at given time points by 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT) assay using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany). UV absorption was measured 2 h after addition of XTT reagent at 450 nm using a BioTek Synergy HT microplate reader (BioTek Instruments, Inc, Winooski, VT, USA).
Invasion and migration assays
Wound-healing migration assays. Migration assays were performed with SK-Mel-147 (2.5 Â 10 4 cells/well) and SK-Mel-28 (5 Â 10 4 cells/well) cells using Oris Cell Migration Assay (CMA5.101) according to the manufacturer's instructions.
Wound-healing invasion assays. Oris Cell Migration Assay 96-well plates were coated with Geltrex LDEV-free reduced growth factor basement membrane matrix (BME, 18 mg/ml) (A1413202, Invitrogen). SK-Mel-147 cells (2.5 Â 10 4 cells/well) were seeded onto the prepared plates. Oris Cell Seeding Stopper was used to create a wound. The cells were allowed to adhere for 2 h before the stoppers and the medium was removed and overlayed with 50 ml 1:1 mixture of BME and Dulbecco's modified Eagle medium containing 20% fetal bovine serum. To enable polymerization of the 3D overlay, plates were incubated for 1 h at 37 1C and then fresh medium containing 10% fetal bovine serum was replenished. Cells were allowed to invade the BME gel for 48 h. The images of the wound area were taken at different time points with BZ-9000 fluorescence microscope and analysed using a BZ-II analyser (Keyence, Neu-Isenburg, Germany).
Lentiviral WEE1 cDNA transduction
Stably WEE1-expressing SK-Mel-28 melanoma cells termed SK-Mel-28-WEE1 cells were generated by infecting SK-Mel-28 cells with commercially available pre-made lentiviral particles (LVP252, Gentarget Inc., San Diego, CA, USA), according to the manufacturer's specifications. Positively transduced cells were double-selected for blasticidin (6 mg/ml) resistance and red fluorescence protein expression. This medium was replaced by normal culture medium 24 h before start of experiments.
Colony-forming assay. SK-Mel-28-control or SK-Mel-28-WEE1 cells were seeded at low density (500 cells/well) in a 6-well plate and allowed to grow for 10-12 days. The cells were then stained with 0.1% crystal violet and analysed microscopically. Quantification was performed by counting total number of colonies in each well.
Statistics
Statistical significance of differential expressions were analysed by unpaired t-test or Mann-Whitney U-test as indicated in the figure legends. Statistical evaluation for proliferation, migration and invasion assays was performed by means of analysis of variance; Bonferroni post tests were used for pairwise comparisons. Pp0.05 were regarded as statistically significant.
